VTRSGeneric and branded pharmaceuticals
Viatris
- Price
- $19.63
- Discount category
- Pricey
- Analysts
- Bullish
- Next earnings
- Feb 25 · · estimated
- Pick status
- Research only
In short
- Thesis
- The market doubts that Viatris can return to growth while its Nashik plant is shut and generic prices stay under pressure, and the restart of the plant and the Pacira purchase through 2027 can lift its value.
- Gap
- Can close. The Pacira closing, expected by the end of November 2026, the restart of the Nashik plant in Q1 2027 and the Q4 2026 report, expected in late February 2027, show whether sales return to growth.
Company guidance: 2026 revenue $14.7 to $14.9 billion; adjusted EBITDA $4.45 to $4.55 billion; adjusted EPS $2.56 to $2.63 (, Q3 2026 results release (8-K))
Price history
About
Viatris Inc. (Viatris) is based in Canonsburg, Pennsylvania. It sells generic medicines and brands, and it is building a smaller group of newer medicines such as RYZUMVI and Gwyn Lo. It reports four regions: Developed Markets, Emerging Markets, JANZ and Greater China. Revenue was $3,749.5 million in Q3 2026 and $11,023.3 million for nine months.
Brands made $2,461.4 million of Q3 net sales and Generics made $1,273.3 million. Adjusted EBITDA was $1,195.7 million in Q3. The common stock trades on Nasdaq in US dollars. Viatris files 10-K and 10-Q reports.
Thesis
The price of Viatris depends on whether it can turn flat revenue into growth while it carries $12.9 billion of debt. Q3 2026 revenue of $3.75 billion matched the year before, because supply limits in Europe and Emerging Markets and new competition held sales back. Adjusted EBITDA rose 4% to $1.20 billion, and Viatris raised the midpoints of all its 2026 guidance. It suspended production at its Nashik plant in India in October, which costs about $100 million of revenue in Q4.
For the price to hold or rise, four things must be true. The Nashik plant must restart in Q1 2027. New products must reach about $450 million of revenue in 2026 and keep growing. The Pacira purchase, for $1.65 billion in cash, must close and add earnings without a large rise in leverage.
The legal cases must not bring a large payment. The closing of Pacira, expected by the end of November 2026, and the Q4 2026 report, expected in late February 2027, are the next tests.
Checkpoints
- Nov 2026 · est.Due this monthPacira purchase closesThe purchase closes by the end of November 2026 at $36.50 per share in cash and Viatris says that gross leverage changes little, and this passes; a delay past the end of 2026 or a higher price fails.
- Feb 25, 2027 · est.PendingQ4 2026 results and 2027 outlook2026 adjusted EBITDA is in the guided range of $4.45 billion to $4.55 billion and the 2027 outlook shows growth, and this passes; a miss or a flat outlook fails.
- Q1 2027 · est.PendingNashik plant restartsProduction at the Nashik plant restarts in Q1 2027, as Viatris expects, and this passes; a later restart fails.
Recent events
- November 17, 2026Viatris completed its purchase of Pacira BioSciences on 17 November 2026. Holders of about 66.46% of Pacira shares tendered them at $36.50 per share in cash. The total price is about $1.69 billion, paid with cash and short-term loans.
- November 5, 2026Viatris reported Q3 2026 results. Revenue was $3.75 billion, adjusted EBITDA was $1.20 billion, adjusted EPS was $0.71 and the GAAP net loss was $325 million because of a higher tax charge. It raised the midpoints of its 2026 guidance to revenue of $14.7 billion to $14.9 billion, adjusted EBITDA of $4.45 billion to $4.55 billion and adjusted EPS of $2.56 to $2.63. It said that supply constraints cost about $100 million of revenue in Q3 and will cost about $100 million in Q4.
- October 30, 2026Viatris started its tender offer for Pacira BioSciences at $36.50 per share in cash, an equity value of about $1.65 billion. It expects the purchase to close by the end of November 2026.
Show 3 older eventsHide older events
- October 8, 2026Viatris agreed to buy Pacira BioSciences, a maker of non-opioid pain medicines, in a merger agreement for $36.50 per share in cash.
- July 1, 2026Viatris signed a new ¥40,000,000,000 unsecured term loan facility with Mizuho Bank. It repays the earlier loan of the same size from 2021.
- June 17, 2026Viatris sold €650 million of 4.250% senior notes due 2033. It used the proceeds for the repayment of $1.675 billion of 3.950% senior notes that matured in 2026.
Latest news and filings
- Last earnings
- November 5, 2026 (8-K on sec.gov)
- Next earnings
- Expected about February 25, 2027. The company has not confirmed the date.
- 10-QQuarterly report for the period ended Sep 30, 2026Filed vtrs-20260930
- 8-KEarnings release and Other company newsFiled Press release and exhibits
- 8-KNew material agreement and Other company newsFiled Read it on sec.gov
- 10-QQuarterly report for the period ended Jun 30, 2026Filed vtrs-20260630
- 8-KEarnings release and Other company newsFiled Press release and exhibits
- 8-KNew material agreement and New debt or financial obligationFiled Read it on sec.gov
- 8-KNew material agreement and New debt or financial obligationFiled Read it on sec.gov
- 8-KOther company newsFiled Read it on sec.gov
- 8-KShareholder vote resultsFiled Read it on sec.gov
- 10-QQuarterly report for the period ended Mar 31, 2026Filed vtrs-20260331
Risks
Bull case: A restart of the Nashik plant in Q1 2027 and the Pacira purchase can return Viatris to growth, as new products reach about $450 million of revenue in 2026.
- A plant is shut. The FDA rated the Nashik plant in India Official Action Indicated, and Viatris suspended production in October. It expects to restart in Q1 2027, but more FDA action can delay this.
- Debt is large. Total debt at notional amounts was $12,924.0 million at September 30, 2026, which is 2.9 times adjusted EBITDA. Of the carrying amount, $1,727.5 million was current. The Pacira purchase uses cash and debt.
- Legal cases are open. Putative class actions and stockholder derivative actions filed since 2023 and a class action filed in 2025 are pending, and the Attorney General of Mississippi sent a subpoena about EpiPen in June 2024. Viatris also carries liabilities for legal matters of the Upjohn business.
- Generic sales are under pressure. Generics net sales fell 3% in Q3 2026, with supply constraints in Europe and Emerging Markets and new competition on some products.
- GAAP earnings are not steady. The Q3 2026 net loss of $325.3 million came mainly from a tax charge on losses in places where Viatris gets little tax benefit. The chief financial officer role is held by an interim officer.
Key statistics
- Market cap
- $23B
- Shares of Nov 2, 2026
- Dividend yield
- 2.4%
- Current annual rate, at the price of Nov 20, 2026
- EPS (trailing)
- -$0.53
- 12 months to Sep 30, 2026
- 52-week range
- $10.15 – $21.20
- To Nov 12, 2026
- Beta
- 0.88
- Vs S&P 500, 5 years monthly, to Oct 30, 2026
- Average volume
- 8.8M
- 3 months, to Nov 12, 2026
Check the numbers:ExchangeGoogle FinanceYahoo FinanceSEC filings
Balance sheet
- Cash
- $1.8B
- Debt
- $12.9B
- Net debt
- $11.1B
Cash against debt
debt covered by cashnet debt $11.1B
When the debt is due
The last debt is due in 2048.
At September 30, 2026, Viatris had total debt at notional amounts of $12,924.0 million. The carrying amount was $13,315.0 million, of which $1,727.5 million was current. Cash and cash equivalents were $1,789.2 million. Gross debt was 2.9 times adjusted EBITDA of the last four quarters. The notes due in 2027 are $969.3 million of euro notes and $754.2 million of dollar notes at carrying amounts. Operating cash flow was $1,669.5 million and free cash flow was $1,491.1 million for nine months. Viatris returned about $717 million to shareholders in nine months, including about $300 million of share repurchases, and about $700 million remains in its program. The purchase of Pacira for about $1.65 billion in cash is not in these figures.
Dividends
- Dividend yield
- 2.4% (current annual rate, at today’s price of $19.63)
- Paid per share
- $0.48 in the last 12 months (4 payments)
- Current annual rate
- $0.48 ($0.12 × 4 a year)
- Latest ex-dividend date
- August 21, 2026, $0.12 per share
Dividends per share by year
| 2022 | $0.48 | |
|---|---|---|
| 2023 | $0.48 | |
| 2024 | $0.48 | |
| 2025 | $0.48 |
Some payments of 2021 are missing in the data, so no bar is shown for that year.
Source: company filings and market data, read on November 12, 2026. The ex-dividend date is the first day a buyer no longer gets the next payment.
Questions about Viatris
What does Viatris do?
Viatris Inc. (Viatris) is based in Canonsburg, Pennsylvania. It sells generic medicines and brands, and it is building a smaller group of newer medicines such as RYZUMVI and Gwyn Lo. Its market cap is $23B at the current price of $19.63.
When does Viatris report earnings next?
This is an estimate: Viatris may report on February 25, 2027. It last reported results on November 5, 2026.
Is Viatris stock below its intrinsic value?
Viatris stock is pricey. This is general information, not advice.
What changed recently at Viatris?
The latest update is from November 17, 2026. Viatris completed its purchase of Pacira BioSciences on 17 November 2026.
What are the main risks for Viatris?
A plant is shut. Debt is large. Legal cases are open.
How much debt and cash does Viatris have?
At September 30, 2026, Viatris had $12.9B of debt and $1.8B of cash.
Does Viatris pay a dividend?
Yes. The current annual dividend of Viatris is $0.48 per share. That is a dividend yield of 2.4% at the current price of $19.63. The latest ex-dividend date was August 21, 2026.
Valuation against peers
| Company | P/E, last 4 quarters | EV/EBITDA, last year | Free cash flow yield, last year | 10-year average P/E |
|---|---|---|---|---|
| VTRSViatris | n/a | 251.7x | 8.6% | n/a |
| ABBVAbbVie | 49.3x | n/a | 3.5% | 37.4x |
| CORCencora | 25.2x | 20.0x | 5.0% | 23.9x |
| BMYBristol Myers Squibb | 13.0x | n/a | 10.7% | 29.8x |
| PCGPG&E | 10.2x | n/a | -8.3% | 17.0x |
| Peer median | 19.1x | n/a | 4.2% | n/a |
- Its free cash flow yield is 8.6%, 4.4 points above the peer median of 4.2%.
The peers are the companies on this site most like VTRS. The multiples come from company filings and today's price, and P/E uses GAAP diluted EPS. Picks shows no analyst forecast: the only look ahead is a company's own EPS guidance, where it gives one. EV/EBITDA is left out for banks, insurers and real estate companies. This is general information, not advice.
Similar companies
- GSKGSKShares: Regulation and courts, High debt
- Intrinsic value
- Below intrinsic value
- Gap
- Slow
- ABBVAbbVieShares: Regulation and courts, High debt
- Intrinsic value
- Far above intrinsic value
- Gap
- Can close
- CORCencoraShares: Regulation and courts, High debt
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
- PCGPG&EShares: Regulation and courts, High debt
- Intrinsic value
- Far below intrinsic value
- Gap
- Will probably not close
- HONAHoneywell AerospaceShares: High debt, Regulation and courts
- Intrinsic value
- Deep below intrinsic value
- Gap
- Can close
Loading your notes…
Read it all? Star VTRS or pass, then go on to the next one.